Cronos Group Inc. (CRON) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $2.72. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CRON = $7.81 (+187.1% from the current price, the stock appears undervalued). Analyst consensus target is CRON = $2 (-15.4% upside).
Valuation: CRON trades at a trailing Price-to-Earnings (P/E) of -102.1 (S&P 500 average ~25).
Financials: revenue is $193M, +31.4%/yr average growth. Net income is $9M (loss), growing at +29.6%/yr. Net profit margin is -4.9% (negative). Gross margin is 32.5% (+15.7 pp trend).
Balance sheet: total debt is $2M against $1.1B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 19.59 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $1.2B.
Analyst outlook: 3 / 15 analysts rate CRON as buy (20%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 49/100 (Partial), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 56/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
